Drugs / ABM-1310
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05892653 | Jun 2023 → Aug 2024 | primary brain neoplasm | ABM Therapeutics Shanghai Company Limited | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05501912 | Sep 2022 → Jun 2024 | neoplastic disease or syndrome | ABM Therapeutics Shanghai Company Limited | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04190628 | Jun 2020 → Apr 2024 | neoplastic disease or syndrome | ABM Therapeutics Corporation | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABM-1310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05501912 ↗ |
| Modality | Small molecule | — CHEMBL6068566 ↗ |
| Route | Oral | “Starting dose at 25 mg by mouth twice daily.” NCT04190628 ↗ |